tradingkey.logo

ATAI Life Sciences NV

ATAI
View Detailed Chart
3.770USD
+0.360+10.56%
Close 02/06, 16:00ETQuotes delayed by 15 min
906.45MMarket Cap
LossP/E TTM

ATAI Life Sciences NV

3.770
+0.360+10.56%
Intraday
1m
30m
1h
D
W
M
D

Today

+10.56%

5 Days

+0.27%

1 Month

-5.75%

6 Months

-10.02%

Year to Date

-7.82%

1 Year

+77.83%

View Detailed Chart

Key Insights

ATAI Life Sciences NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.45.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ATAI Life Sciences NV's Score

Industry at a Glance

Industry Ranking
106 / 392
Overall Ranking
236 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

ATAI Life Sciences NV Highlights

StrengthsRisks
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.19% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 308.00K.
Fairly Valued
The company’s latest PE is -4.56, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 45.07M shares, increasing 0.04% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.02M shares of this stock.

Analyst Rating

Based on 13 analysts
Buy
Current Rating
12.455
Target Price
+265.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ATAI Life Sciences NV News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

ATAI Life Sciences NV Info

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
Ticker SymbolATAI
CompanyATAI Life Sciences NV
CEORao (Srinivas G)
Websitehttps://www.atai.com/
KeyAI